Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people taking a GLP-1 weight loss injection notice reduced appetite within the first one to four weeks. Measurable weight loss typically follows in weeks two to four, with the most significant changes seen across months three to six as the dose increases. Results build gradually — and that is by design, not a flaw. These are prescription-only medicines, and a prescriber needs to assess whether they're right for you before you start.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
That's probably the question sitting at the back of your mind right now, especially if you've read about 20% weight loss in trials and then stepped on the scales after two weeks and seen almost nothing move. It's a fair frustration, and it has a straight answer.
Both tirzepatide (Mounjaro) and semaglutide (Wegovy) begin at a tolerability dose. The 2.5mg starting pen for tirzepatide and the 0.25mg starting dose for semaglutide exist so your gut can adjust to the medicine, not to treat weight directly. Side effects like nausea and indigestion are most common early on, and a lower starting dose keeps them manageable. The NHS medicines information for tirzepatide on the NHS website explains this clearly: the dose is increased gradually by your prescriber over several months.
Most people do notice appetite changes even at the starter dose, feeling full sooner, less interest in snacking between meals, a quieter internal monologue about food. That is the medicine working, and if you want to understand what symptoms to expect from a weight loss injection as your body adjusts, our dedicated page covers the early signs in detail. You can read more about the underlying mechanism on our how weight loss injections work page.
For most people in the clinical trials, meaningful weight loss (defined as around 5% of starting body weight) appeared by months two to three. By month six, many participants were well past that threshold. The headline figures come from longer follow-up: SURMOUNT-1, which ran for 72 weeks, recorded an average body-weight reduction of around 20–21% at the 15mg tirzepatide dose, and the STEP 1 trial found an average reduction of around 15% over 68 weeks with semaglutide 2.4mg. Both are published in the New England Journal of Medicine.
The pattern in real life tends to follow a similar arc: slower in the first eight weeks, then steadier losses through months three to nine as the therapeutic dose is reached, then a gradual plateau. The plateau is not a failure; it is the body finding a new equilibrium. If you want a closer look at how long weight loss injections take to work and how the changes tend to arrive phase by phase, the how fast weight loss injections work page breaks it down in further detail.
One thing worth knowing: individual variation is real. Some people lose quickly at lower doses. Others need the full titration. Neither outcome means the treatment is working or failing, it means bodies are different.
Yes, in most cases. The trials show that weight tends to return (partly or substantially) after the medicine is stopped. This is one reason these treatments are prescribed as part of a broader approach to weight management, alongside changes to diet and activity. It is also why your prescriber will review your progress before every repeat, not simply renew automatically. At nume, at our pharmacy, a prescriber reads your update before each repeat order goes out, without exception.
The question of how long you might stay on treatment is a clinical one. NICE's recommendation for semaglutide (TA875) specifies a maximum of two years' use within a specialist service, and reviews the position if less than 5% weight loss is achieved after six months on the maintenance dose. NICE's full guidance covers the criteria in detail. For tirzepatide, a similar review applies if progress is insufficient at the highest tolerated dose. Your prescriber will discuss this with you based on your specific situation.
Several things interact with the timeline: starting weight, how consistently you take the injection on the same day each week, what you eat alongside it, how active you are, and whether any other medicines or conditions affect the response. Injection technique and site rotation matter too, poor absorption from a single overused site can blunt the effect. The weight loss injections overview covers the practical side of getting each dose right.
Sleep and stress are less-discussed but genuinely relevant. Chronically poor sleep and high cortisol work against appetite regulation. The injection changes the hormonal signal, but it cannot override everything else. Thinking about your overall approach to weight loss alongside the medicine is worth the time.
If you're thinking about starting treatment and wondering whether you'd be suitable, our guide to getting weight loss injections walks through the eligibility criteria and what a consultation involves. And if you'd like to understand the cost context before you begin, the treatment and pricing page lays out exactly what's included.
The clearest way to understand your own likely timeline is to speak with a prescriber who knows your health picture. Our clinical team reviews every consultation personally, if treatment is suitable, you'll have a real conversation about what to expect, not a generic timeline from a leaflet. Speak to our prescribers through a free consultation, and get an honest assessment.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.